Вже доступно! Дослідження Telegram за 2025 — головні інсайти року 
RESPIRATORY Medicine / Pulmonology Updates
Відкрити в Telegram
All the atest articles, research and news from worlds leading Pulmonology Journals. Discussion Group https://t.me/Medical_Professionals_Forum Contact us https://t.me/Contact_Updates_in_Medicine_Bot
Показати більше4 930
Підписники
+624 години
+317 днів
+12630 день
Триває завантаження даних...
Схожі канали
Хмара тегів
Вхідні та вихідні згадування
---
---
---
---
---
---
Залучення підписників
липень '26
липень '26
+41
в 0 каналах
червень '26
+139
в 0 каналах
Get PRO
травень '26
+160
в 0 каналах
Get PRO
квітень '26
+158
в 0 каналах
Get PRO
березень '26
+107
в 0 каналах
Get PRO
лютий '26
+110
в 0 каналах
Get PRO
січень '26
+98
в 0 каналах
Get PRO
грудень '25
+102
в 0 каналах
Get PRO
листопад '25
+112
в 2 каналах
Get PRO
жовтень '25
+38
в 1 каналах
Get PRO
вересень '25
+2
в 0 каналах
Get PRO
серпень '25
+7
в 0 каналах
Get PRO
липень '25
+8
в 0 каналах
Get PRO
червень '25
+7
в 1 каналах
Get PRO
травень '25
+8
в 0 каналах
Get PRO
квітень '25
+13
в 0 каналах
Get PRO
березень '25
+11
в 0 каналах
Get PRO
лютий '25
+19
в 0 каналах
Get PRO
січень '25
+36
в 1 каналах
Get PRO
грудень '24
+58
в 0 каналах
Get PRO
листопад '24
+237
в 3 каналах
Get PRO
жовтень '24
+214
в 0 каналах
Get PRO
вересень '24
+170
в 0 каналах
Get PRO
серпень '24
+144
в 0 каналах
Get PRO
липень '24
+82
в 1 каналах
Get PRO
червень '24
+85
в 0 каналах
Get PRO
травень '24
+62
в 1 каналах
Get PRO
квітень '24
+58
в 0 каналах
Get PRO
березень '24
+53
в 0 каналах
Get PRO
лютий '24
+121
в 0 каналах
Get PRO
січень '24
+192
в 0 каналах
Get PRO
грудень '23
+229
в 0 каналах
Get PRO
листопад '23
+47
в 0 каналах
Get PRO
жовтень '23
+66
в 3 каналах
Get PRO
вересень '23
+40
в 0 каналах
Get PRO
серпень '23
+72
в 0 каналах
Get PRO
липень '23
+62
в 0 каналах
Get PRO
червень '23
+70
в 0 каналах
Get PRO
травень '23
+69
в 0 каналах
Get PRO
квітень '23
+68
в 0 каналах
Get PRO
березень '23
+80
в 0 каналах
Get PRO
лютий '23
+67
в 0 каналах
Get PRO
січень '23
+80
в 0 каналах
Get PRO
грудень '22
+87
в 0 каналах
Get PRO
листопад '22
+265
в 0 каналах
Get PRO
жовтень '22
+68
в 0 каналах
Get PRO
вересень '22
+96
в 0 каналах
Get PRO
серпень '22
+72
в 0 каналах
Get PRO
липень '22
+79
в 0 каналах
Get PRO
червень '22
+119
в 0 каналах
Get PRO
травень '22
+125
в 0 каналах
Get PRO
квітень '22
+127
в 0 каналах
Get PRO
березень '22
+61
в 0 каналах
Get PRO
лютий '22
+35
в 0 каналах
Get PRO
січень '22
+49
в 0 каналах
Get PRO
грудень '21
+25
в 0 каналах
Get PRO
листопад '21
+39
в 0 каналах
Get PRO
жовтень '21
+48
в 0 каналах
Get PRO
вересень '21
+29
в 0 каналах
Get PRO
серпень '21
+39
в 0 каналах
Get PRO
липень '21
+50
в 0 каналах
Get PRO
червень '21
+74
в 0 каналах
Get PRO
травень '21
+41
в 0 каналах
Get PRO
квітень '21
+192
в 0 каналах
Get PRO
березень '21
+250
в 0 каналах
Get PRO
лютий '21
+41
в 0 каналах
Get PRO
січень '21
+60
в 0 каналах
Get PRO
грудень '20
+703
в 0 каналах
| Дата | Залучення підписників | Згадування | Канали | |
| 08 липня | +2 | |||
| 07 липня | +6 | |||
| 06 липня | +3 | |||
| 05 липня | +3 | |||
| 04 липня | +5 | |||
| 03 липня | +11 | |||
| 02 липня | +5 | |||
| 01 липня | +6 |
Дописи каналу
[Articles] Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00142-6/fulltext?rss=yes
The dual-oral chemotherapy-free regimen of ifebemtinib plus garsorasib had encouraging efficacy with a manageable safety profile as first-line treatment for KRASG12C-mutated NSCLC. A randomised phase 3 study has been initiated to further validate these findings against standard-of-care in the first-line setting (NCT07174908).
| 2 | [Comment] FAK co-inhibition in KRASG12C-mutated non-small-cell lung cancer
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00184-0/fulltext?rss=yes
The therapeutic strategy of targeting KRASG12C mutations has yielded response rates of 28–56% and median progression-free survival of 5·6–13·8 months in pretreated non-small-cell lung cancer (NSCLC).1 Yet response durability remains poor in most patients, restricting broader use, particularly in first-line settings. Resistance emerges early during treatment through intrinsic or acquired mechanisms, such as adaptive RAS–MAPK reactivation, bypass-pathway signalling, and stromal-mediated and microenvironment-mediated escape. | 81 |
| 3 | [Personal View] Asthma diagnosis in adults and children: challenges, future directions, and a call to action
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00143-8/fulltext?rss=yes
Asthma is the most common chronic airway disease worldwide, imposing substantial clinical, societal, and economic burden. Asthma is generally defined as a heterogeneous clinical syndrome characterised by fluctuating respiratory symptoms and variable expiratory airflow limitation. Despite this definition, asthma misdiagnosis remains high; 20–70% of individuals with asthma remain undiagnosed and untreated, and approximately 30% of those labelled as having asthma do not have the disease. Objective evidence, alongside variability of symptoms, is essential to support a diagnosis of asthma. | 174 |
| 4 | [Articles] PERC-Peds rule for bedside exclusion of pulmonary embolism without radiation in children in the USA (BEEPER): a multicentre, prospective, observational, diagnostic accuracy study
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00086-X/fulltext?rss=yes
In this multicentre, prospective, observational, diagnostic accuracy study of children with suspected pulmonary embolism in the emergency department, we found a 6·3% prevalence of pulmonary embolism or proximal DVT; in this population, the PERC-Peds negative rule can safely rule out pulmonary embolism. Use of PERC-Peds might reduce low-value diagnostic testing for pulmonary embolism in children and adolescents. | 312 |
| 5 | [Comment] Intensive care in global conflicts: brace for impact
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00186-4/fulltext?rss=yes
Not a day goes by without the news reporting new and ongoing conflicts globally. Over the past few decades, the frequency and complexity of both intrastate and interstate conflicts have increased, with consequences extending beyond geopolitical boundaries into everyday life, including health-care systems.1 This evolving context raises the question of what the implications are for health-care professionals in the intensive care unit (ICU). | 280 |
| 6 | [Comment] The PERC-Peds rule: a promising step towards structured pulmonary embolism risk assessment in children
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00222-5/fulltext?rss=yes
Pulmonary embolism accounts for 10–15% of all paediatric venous thromboembolism (VTE) events, with an annual incidence of 0·14–0·9 per 100 000 children.1,2 Although rare, pulmonary embolism is a severe and potentially life-threatening complication in children.1 In adults, efforts to improve pulmonary embolism diagnosis have focused on increasing the accuracy of risk-stratification tools to reduce unnecessary testing and overtreatment.3 By contrast, in children, the main challenge has been delayed recognition and underdiagnosis. | 245 |
| 7 | [News] RSV vaccination and immunisation programmes accelerating worldwide
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00223-7/fulltext?rss=yes
Respiratory syncytial virus (RSV) has been a continuous and major cause of morbidity and mortality in babies and older people, adding pressure to strained hospitals in their busy winter seasons in countries of all incomes, while of course causing the highest mortality in low-income and middle-income countries (LMICs). According to WHO estimates, each year, RSV causes more than 3·6 million hospitalisations and around 100 000 deaths in children under 5 years of age. Most paediatric RSV deaths (97%) occur in LMICs where there is limited access to supportive medical care. | 226 |
| 8 | [Correspondence] Precision-guided immunomodulatory therapy in sepsis
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00153-0/fulltext?rss=yes
Erik H A Michels and colleagues developed a parsimonious three-biomarker framework (procalcitonin, soluble TREM-1, and IL-6) that quantifies the Dysregulated Immune Profile (DIP) as a continuous score (cDIP) beyond organ-failure-based clinical surrogates and identifies patients with differential responses to hydrocortisone.1 | 352 |
| 9 | [Correspondence] Precision-guided immunomodulatory therapy in sepsis – Authors’ reply
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00155-4/fulltext?rss=yes
We agree with Yingying Yang and colleagues that similar continuous Dysregulated Immune Profile (cDIP) values could arise from different host–pathogen configurations. Robustly decomposing immune dysregulation into discrete pathogen-driven versus host-driven components is challenging, as these processes are intrinsically coupled. Pathogen burden, identity, and infection source undoubtedly shape the host response, yet substantial heterogeneity in immune dysregulation persists within each of these factors (see appendix 2 p 39 of the original Article1). | 315 |
| 10 | [Correspondence] Precision-guided immunomodulatory therapy in sepsis
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00154-2/fulltext?rss=yes
We commend Erik H A Michels and colleagues1 for quantifying immune dysregulation in pneumonia and sepsis. Through dimensionality reduction and clustering with 35 biomarkers, they defined three Dysregulated Immune Profiles (DIPs) and a corresponding continuous score (cDIP). By training parsimonious models with three biomarkers, they facilitated the application of these clusters and score to datasets without extensive data, such as a subset (n=425) of the CAPE-COD trial2 (hydrocortisone vs placebo in community-acquired-pneumonia). | 277 |
| 11 | [Editorial] Dying with Dignity—time to cut the red tape
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00198-0/fulltext?rss=yes
While death is a certainty for us all, how and when we die is not. For people with a terminal illness, the reality of death must be confronted alongside common fears of prolonged pain and suffering as well as a loss of autonomy. Although good end-of-life care can manage most symptoms, there are some circumstances that cannot be palliated and a person might feel their quality of life is so poor they would prefer to die. The practice of medical aid in dying (MAiD; also called physician assisted death) allows someone with a terminal diagnosis to obtain medication from a physician to end their life. | 257 |
| 12 | [News] 2026 GINA report for asthma
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00188-8/fulltext?rss=yes
On May 5, 2025, the Global Initiative For Asthma (GINA) published the 2026 update to their Global Strategy for Asthma Management and Prevention. On the same date, an online discussion hosted by GINA panel members and the European Respiratory Society gave an overview of the major changes. | 237 |
| 13 | [Comment] Heterogeneity of severe asthma in Europe: a SHARP-er view
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00165-7/fulltext?rss=yes
Disease-modifying anti-asthmatic drugs, especially biologics, have fundamentally changed the therapeutic landscape of severe asthma, making asthma remission a realistic treatment goal in many patients.1 Although asthma remission concepts continue to evolve, definitions include minimal asthma symptoms, no exacerbations, no use of systemic corticosteroids, and stable or normal lung function, for at least 12 months.2 It has become evident that several challenges reduce remission rates in patients with severe asthma. | 465 |
| 14 | [Articles] Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00052-4/fulltext?rss=yes
The application of standardised criteria for diagnosing pulmonary fibrosis enables identification of affected children among patients with chILD. These children have lower pulmonary function, an increased risk of death, and could benefit from antifibrotic therapies. | 434 |
| 15 | [Articles] Severe asthma and remission prospects in Europe (SHARP): insights from a multicentre observational study based on the European Severe Asthma Registry
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00141-4/fulltext?rss=yes
This pan-European analysis of severe asthma revealed significant clinical heterogeneity and a substantial disease burden despite advanced therapies, highlighting the enduring nature of type 2 inflammation, the potential inadequacy of current remission strategies with available therapeutic approaches, and the necessity for early identification of high-risk patients. | 390 |
| 16 | [Comment] Pulmonary fibrosis in chILD: bridging the gap
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00117-7/fulltext?rss=yes
Childhood interstitial lung disease (chILD) encompasses a group of rare, heterogeneous respiratory conditions associated with substantial morbidity and mortality ranging from 1% to 30% during childhood.1,2 The exact causes of death can differ for each one of the diverse entities.1 In adult ILD, fibrosis is the major component defining progression and carries a dismal prognosis.3 It is a tissue repair response to injury that becomes maladaptive or manifests as a failure of tissue regenerative capacity and has, so far, no effective treatment. | 340 |
| 17 |  Evidence. Education. Better Care.
Latest medical research, guideline updates, and news—all in one place.
https://whatsapp.com/channel/0029VagObEL3rZZbSTrZSU03 | 378 |
| 18 | [Corrections] Correction to Lancet Respir Med 2026; published online May 28. https://doi.org/10.1016/S2213-2600(26)00160-8
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00199-2/fulltext?rss=yes
Moitra S, Annesi-Maesano I, Alghamdi MS, et al. Toxic skies of war. Lancet Respir Med 2026; published online May 28. https://doi.org/10.1016/S2213-2600(26)00160-8—In the Declaration of interests section of this Correspondence, the statements for Sara De Matteis and Ane Johannessen have been corrected. These corrections have been made to the online version as of June 22, 2026, and will be made to the printed version. | 383 |
| 19 | [News] Trump Administration sparks furore and resignations over fruit-flavoured vape authorisations
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00190-6/fulltext?rss=yes
On May 5, the White House overruled objections from US Food and Drug Administration (FDA) commissioner Marty Makary and ordered the agency to authorise sales of two fruit-flavoured e-cigarette products. | 475 |
| 20 | [Correspondence] Precision-guided immunomodulatory therapy in sepsis
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(26)00153-0/fulltext?rss=yes
Erik H A Michels and colleagues developed a parsimonious three-biomarker framework (procalcitonin, soluble TREM-1, and IL-6) that quantifies the Dysregulated Immune Profile (DIP) as a continuous score (cDIP) beyond organ-failure-based clinical surrogates and identifies patients with differential responses to hydrocortisone.1 | 450 |
